Issue navigation
Volume 9, Issue 7, November 2023
EDITORIAL
Antiplatelet treatment after PCI
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 593–594, https://doi.org/10.1093/ehjcvp/pvad071
PHARMAPULSE
2023 ESC Guidelines on ACS: what is new in antithrombotic therapy?
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 595–596, https://doi.org/10.1093/ehjcvp/pvad065
What's new in pharmacotherapy at ESC Congress 2023?
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 597–598, https://doi.org/10.1093/ehjcvp/pvad064
EDITORIAL
Reducing the risks of nuclear war: the role of health professionals
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 599–600, https://doi.org/10.1093/ehjcvp/pvad060
ORIGINAL ARTICLES
Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 601–607, https://doi.org/10.1093/ehjcvp/pvad023
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 608–616, https://doi.org/10.1093/ehjcvp/pvad027
Bleeding risk and P2Y12 inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 617–626, https://doi.org/10.1093/ehjcvp/pvad048
Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 627–635, https://doi.org/10.1093/ehjcvp/pvad041
Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 636–646, https://doi.org/10.1093/ehjcvp/pvad051
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 647–657, https://doi.org/10.1093/ehjcvp/pvad055
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 658–665, https://doi.org/10.1093/ehjcvp/pvad028
CORRESPONDENCE
Bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 666–668, https://doi.org/10.1093/ehjcvp/pvad029
P2Y12 inhibition in high bleeding risk patients: making the right decision in a complex setting
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Page 669, https://doi.org/10.1093/ehjcvp/pvad056
